Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.

Austin JA, Jenkins RE, Austin GM, Glenn MA, Dunn K, Scott L, Lucas CM, Clark RE.

Biochem J. 2019 Aug 15;476(15):2255-2269. doi: 10.1042/BCJ20190121.

PMID:
31350330
2.

Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.

Kim MO, Choe MH, Yoon YN, Ahn J, Yoo M, Jung KY, An S, Hwang SG, Oh JS, Kim JS.

Biochem Pharmacol. 2017 Nov 15;144:78-89. doi: 10.1016/j.bcp.2017.08.009. Epub 2017 Aug 13.

PMID:
28813646
3.

Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.

Khanna A, Pimanda JE, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6548-53. doi: 10.1158/0008-5472.CAN-13-1994. Epub 2013 Nov 7. Review.

4.

Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, Lee MS, Yang Y.

J Biol Chem. 2014 Jan 3;289(1):28-40. doi: 10.1074/jbc.M113.507954. Epub 2013 Nov 8.

5.

Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefström J, Aittokallio T, Weiss C, Ristimäki A, Visakorpi T, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6757-69. doi: 10.1158/0008-5472.CAN-13-1002. Epub 2013 Sep 26.

6.

ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.

Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J.

PLoS One. 2011 Mar 22;6(3):e17979. doi: 10.1371/journal.pone.0017979.

7.

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.

Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, Chen KF.

PLoS One. 2013;8(2):e55705. doi: 10.1371/journal.pone.0055705. Epub 2013 Feb 1.

8.

Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.

Nath S, Ohlmeyer M, Salathe MA, Poon J, Baumlin N, Foronjy RF, Geraghty P.

Am J Respir Cell Mol Biol. 2018 Dec;59(6):695-705. doi: 10.1165/rcmb.2018-0173OC.

PMID:
30011381
9.

Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.

Huang Q, Qin S, Yuan X, Zhang L, Ji J, Liu X, Ma W, Zhang Y, Liu P, Sun Z, Zhang J, Liu Y.

Oncol Rep. 2017 Jul;38(1):598-606. doi: 10.3892/or.2017.5667. Epub 2017 May 24.

PMID:
28560452
10.

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF.

Breast Cancer Res. 2014 Sep 17;16(5):431. doi: 10.1186/s13058-014-0431-9.

11.

CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.

Peng B, Lei N, Chai Y, Chan EK, Zhang JY.

Mol Biosyst. 2015 Jan;11(1):105-14. doi: 10.1039/c4mb00513a. Epub 2014 Oct 17.

12.

Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.

Li S, Feng TT, Guo Y, Yu X, Huang Q, Zhang L, Tang W, Liu Y.

Oncol Lett. 2016 Dec;12(6):5370-5376. doi: 10.3892/ol.2016.5374. Epub 2016 Nov 9.

13.

CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.

Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL.

Oncogene. 2010 Nov 25;29(47):6257-66. doi: 10.1038/onc.2010.357. Epub 2010 Aug 23.

PMID:
20729919
14.

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF.

Biochem Pharmacol. 2013 Feb 1;85(3):356-66. doi: 10.1016/j.bcp.2012.11.009. Epub 2012 Nov 23.

PMID:
23178652
15.

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.

Liu CY, Huang TT, Chen YT, Chen JL, Chu PY, Huang CT, Wang WL, Lau KY, Dai MS, Shiau CW, Tseng LM.

EBioMedicine. 2019 Feb;40:263-275. doi: 10.1016/j.ebiom.2018.12.032. Epub 2019 Jan 14.

16.

Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

Yu HC, Hung MH, Chen YL, Chu PY, Wang CY, Chao TT, Liu CY, Shiau CW, Chen KF.

Cell Death Dis. 2014 Jul 31;5:e1359. doi: 10.1038/cddis.2014.325.

17.

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.

Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE.

Blood. 2011 Jun 16;117(24):6660-8. doi: 10.1182/blood-2010-08-304477. Epub 2011 Apr 13.

18.

Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.

Liu X, Cao W, Qin S, Zhang T, Zheng J, Dong Y, Ming P, Cheng Q, Lu Z, Guo Y, Zhang B, Liu Y.

Signal Transduct Target Ther. 2017 May 26;2:17013. doi: 10.1038/sigtrans.2017.13. eCollection 2017.

19.

CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.

Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, Jäättelä M.

J Cell Biol. 2014 Mar 3;204(5):713-27. doi: 10.1083/jcb.201304012.

20.

Ethoxysanguinarine inhibits viability and induces apoptosis of colorectal cancer cells by inhibiting CIP2A.

Jin L, Si Y, Hong X, Liu P, Zhu B, Yu H, Zhao X, Qin S, Xiong M, Liu Y, Luo Z, Guo Y.

Int J Oncol. 2018 Mar 16. doi: 10.3892/ijo.2018.4323. [Epub ahead of print]

PMID:
29568959

Supplemental Content

Support Center